-
WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its Integrated Biologics CRDMO Center in the Fengxian district of Shanghai. The new facility will enhance the company’s development and manufacturing capacity, offering end-to-end services for diversified biologics to accelerate project timelines for global clients. This…
-
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
•
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a licensing deal with US firm Dragonfly Therapeutics. The agreement grants Dragonfly rights to use Nona Bio’s heavy chain only antibody discovery platform (HCAb) technology and develop antibodies according to Dragonfly’s designated targets. Financial details…
-
Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China
•
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing for the Category 1 drug candidate SAL0119 has been accepted for review by the Center for Drug Evaluation (CDE). This marks a significant step forward in the development of SAL0119, an oral small-molecule immunosuppressant designed…
-
Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for the Category 1 biologic product ASKG915 has been accepted for review by the US FDA. This marks a significant step forward in the development of ASKG915, a bifunctional fusion protein targeting programmed-death 1 (PD-1) and…
-
Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for its LB2102, an autologous chimeric antigen receptor-T (CAR-T) therapy designed to treat adult patients with small cell lung cancer (SCLC) by targeting DLL3, a cell surface protein highly expressed in SCLC. Clinical Study DesignThe open-label…
-
Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its Category 1 drug candidate STC007. The study will focus on moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adults receiving hemodialysis (HD).…
-
JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration
•
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership with compatriot firm Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223). The collaboration aims to leverage JD Healthcare’s healthcare supply chain and service advantages, combined with Yuyue Med’s expertise in the medical device field, to enhance…
-
Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version of AbbVie’s auto-immune disease drug Humira (adalimumab) co-developed by Mabwell, has been approved by the National Medical Products Administration (NMPA) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and…
